newsfilter
← Latest News
GlobeNewswire·

Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update

~ Reports KEVEYIS® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021 KEVEYIS® (dichlorphenamide) Revenue Guidance